Effects of entecavir on liver fibrosis indices in patients with hepatogenous diabetes

Objective To investigate the effects of entecavir on liver fibrosis indices in patients with hepatogenous diabetes. Methods A total of 98 patients, who were admitted to our hospital from June 2008 to August 2013, were diagnosed with hepatitis B cirrhosis complicated by hepatogenous diabetes, and were randomly and equally divided into treatment group and control group. All patients were given diabetic diet, as well as liver protection, symptomatic treatment, and supportive care. The treatment group was orally administered entecavir 0. 5 mg once daily for 52 weeks. Live fibrosis indices and Fibro Scan value were analyzed after treatment. Comparison of continuous data between the two groups was made by t test, and comparison of categorical data was made by χ2test. Results Compared with the control group, the treatment group had significantly lower levels of laminin, type Ⅳ collagen, hyaluronic acid, and type Ⅲ procollagen (t = 2. 71, P < 0. 01; t =3. 53, P < 0. 01; t = 2. 34, P < 0. 05; t = 2. 28, P < 0. 05) , a significantly lower Fibro Scan value (t = 3. 22, P < 0. 01) , a significantly higher serum HBV DNA clearance rate (χ2= 12. 69, P < 0. 01) , a significantly lower blood glucose level (t = 16. 01, P < 0. 01) , significantly lower levels of total bilirubin and alanine aminotransferase (t = 5. 53, P < 0. 01; t = 4. 73, P < 0. 01) , and a significantly higher albumin level (t = 2. 42, P < 0. 05) . Conclusion Entecavir leads to improvements in liver fibrosis indices, Fibro Scan value, viral DNA replication, blood glucose, and liver function indices and has good efficacy in HBV DNA-positive hepatitis B cirrhosis patients complicated by hepatogenous diabetes.